Acetophenone

Acetophenone

SCHEMBL713844

CC(=O)c1ccccc1.O=C(c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 2/20 0.61
CES2 O00748 1/20 0.61
CES1 P23141 1/20 0.61
NR4A1 P22736 1/20 0.56
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 2/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
NLRP1 Q9C000 1/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
HPGD P15428 3/20 0.53
ELANE P08246 1/20 0.53
LMNA P02545 2/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetophenone SCHEMBL25304274 0.94 CES2 (0.68) SRD5A2CES2CES1NR4A1ALDH1A1
Acetone SCHEMBL29156010 0.92 SRD5A2 (0.65) SRD5A2CES2CES1NR4A1ALDH1A1
SCHEMBL31186097 0.92 SRD5A2 (0.64) SRD5A2CES2CES1NR4A1SMN1; SMN2
SCHEMBL2610307 0.89 ALDH1A1 (0.70) SRD5A2CES2CES1ALDH1A1SMN1; SMN2
SCHEMBL50462 0.89 SRD5A2 (0.74) SRD5A2CES2CES1NR4A1ALDH1A1
SCHEMBL9442387 0.89 SRD5A2 (0.74) SRD5A2CES2CES1NR4A1ALDH1A1
Hydrochloric Acid SCHEMBL4594202 0.87 SRD5A2 (0.71) SRD5A2CES2CES1NR4A1ALDH1A1
Hydrochloric Acid SCHEMBL4594201 0.87 SRD5A2 (0.71) SRD5A2CES2CES1NR4A1ALDH1A1
Bicarbonate SCHEMBL9817101 0.87 SRD5A2 (0.71) SRD5A2CES2CES1NR4A1ALDH1A1
Acetophenone SCHEMBL28412109 0.87 MAPT (0.58) CES2CES1ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714778-B1 LAMINATE AND PROCESS FOR PRODUCING THE SAME TOKUYAMA CORP (JP) 2018-11-21 EP disclosed
CN-103426743-B The cutting method of semiconductor wafer and the semiconductor machining cutting belt for this method 古河电气工业株式会社 2017-12-08 CN disclosed
US-9588257-B2 Photochromic curable composition TOKUYAMA CORPORATION (JP) 2017-03-07 US disclosed
EP-2554624-B1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORP (JP) 2014-11-05 EP disclosed
US-20140146285-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-05-29 US disclosed
EP-2733155-A1 PHOTOCHROMIC CURABLE COMPOSITION Tokuyama Corporation (JP) 2014-05-21 EP disclosed
US-8663508-B2 Photochromic curable composition TOKUYAMA CORPORATION (JP) 2014-03-04 US disclosed
US-8529789-B2 Curable composition TOKUYAMA CORPORATION (JP) 2013-09-10 US disclosed
EP-2554624-A1 PHOTOCHROMIC CURABLE COMPOSITION Tokuyama Corporation (JP) 2013-02-06 EP disclosed
US-20130015416-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2013-01-17 US disclosed
EP-1445257-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2004-08-11 EP disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-6698883-B2 COLOR DENSITY AND A LARGE FADING RATE, HARDNESS, HEAT RESISTANCE AND SHOCK RESISTANCE; AS OPTICAL MATERIAL SUCH AS A PHOTOCHROMIC LENS MATERIAL TOKUYAMA CORPORATION (JP) 2004-03-02 US disclosed
US-6646104-B1 An optical material in a field where a high degree of refractive index is desired as represented by photochromic plastic lenses. TOKUYAMA CORPORATION (JP) 2003-11-11 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
EP-1291388-A1 CURABLE COMPOSITION AND PHOTOCHROMIC CURED ARTICLE TOKUYAMA CORPORATION (JP) 2003-03-12 EP disclosed
US-20030008958-A1 Curable composition and photochromic cured article TOKUYAMA CORPORATION (JP) 2003-01-09 US disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
EP-1149830-A1 PROCESS FOR PRODUCTION OF SULFUR COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-10-31 EP disclosed
EP-1130038-A1 CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2001-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 SRD5A2 2589/4885CES2 1746/4885CES1 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.